Next Generation Drug Targeting in Dermatology: Alys Pharmaceuticals’ Pioneering Approach
Time: 4:00 pm
day: Conference Day One
Details:
- Optimal benefit/risk outcomes from state-of-the-art tissue and cell-level targeting strategies
- Molecular targeting to sidestep side effects: antibody vectorization for chronic spontaneous urticaria
- Truly sharp targeting: siRNA-based technology for inflammatory skin disease
